Recommendations for the management of tyrosinaemia type 1

Corinne de Laet, Carlo Dionisi-Vici, James V. Leonard, Patrick McKiernan, Grant Mitchell, Lidia Monti, H. Ogierélène de Baulny, Guillem Pintos-Morell, Ute Spiekerkötter

Research output: Contribution to journalArticlepeer-review


The management of tyrosinaemia type 1 (HT1, fumarylacetoacetase deficiency) has been revolutionised by the introduction of nitisinone but dietary treatment remains essential and the management is not easy. In this review detailed recommendations for the management are made based on expert opinion, published case reports and investigational studies as the evidence base is limited and there are no prospective controlled studies.The added value of this paper is that it summarises in detail current clinical knowledge about HT1 and makes recommendations for the management.

Original languageEnglish
Pages (from-to)8
Number of pages1
JournalOrphanet Journal of Rare Diseases
Publication statusAccepted/In press - Jan 11 2013

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Genetics(clinical)
  • Medicine(all)

Fingerprint Dive into the research topics of 'Recommendations for the management of tyrosinaemia type 1'. Together they form a unique fingerprint.

Cite this